Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 15/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22325001 | 0.84 | CHRNB2 (0.45) | TLR9 | |
| SCHEMBL22324835 | 0.82 | LOX (0.42) | ROCK2CYP17A1ACVR1 | |
| SCHEMBL22340525 | 0.80 | HTR2C (0.53) | ROCK2 | |
| SCHEMBL22324795 | 0.80 | TRPV6 (0.50) | ROCK2 | |
| SCHEMBL22324868 | 0.79 | DRD2 (0.49) | — | |
| SCHEMBL22324896 | 0.79 | SLC18A3 (0.41) | ROCK2ACVR1 | |
| SCHEMBL22324988 | 0.79 | TLR9 (0.42) | TLR9TLR7TLR8PROKR1 | |
| SCHEMBL22324908 | 0.78 | ROCK2 (0.40) | ROCK2ACVR1 | |
| SCHEMBL22324870 | 0.78 | ROCK2 (0.46) | ROCK2 | |
| SCHEMBL12093555 | 0.76 | LOX (0.47) | TLR9TLR7TLR8CYP17A1PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | TLR9 4624/4885TLR7 4817/4885TLR8 4608/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | TLR9 4624/4885TLR7 4817/4885TLR8 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.